Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study
PROTEOMICS – Clinical Applications · 2026-05 · 20 (3)
DOI: 10.1002/prca.70043 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PROTEOMICS – Clinical Applications, online erschienen am 29.03.2026. Verfasst von Dana Dlouha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center For Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Hyperlipoproteinemia Type II, Proteome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Ministry of Health of the Czech Republic, Czech Health Research Council, Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a novel approach for reducing low‐density lipoprotein cholesterol (LDL‐C) levels in patients with familial hypercholesterolemia (FH). In our study, we aimed to compare the plasma proteome profiles of heterozygous FH (HeFH) patients and non‐FH patients treated with PCSK9 inhibitors (PCSK9i).
Methods
We analyzed 132 plasma samples from 38 patients. Samples were collected before the start of the PCSK9i treatment and then again at the third, sixth, and 12 th months of treatment. Using LC‒MS technology, we compared two approaches: depleted and nondepleted samples.
Results
Across all time points of treatment, numerous differentially expressed proteins were detected regardless of the FH status compared to baseline. We identified only three proteins with downregulated expression—PCSK9, CRTAC1, and PON1—with p adj
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center For Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
- Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
- Department of Clinical Biochemistry, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
- First Faculty of Medicine, Charles University, Prague, Czech Republic.
- Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.
- 3rd Department of Internal Medicine - Metabolism and Gerontology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
ORCID-Profile: Dana Dlouha
Förderung
- Ministry of Health of the Czech Republic
- Czech Health Research Council
- Ministerstvo Zdravotnictví Ceské Republiky
- Agentura Pro Zdravotnický Výzkum České Republiky
Zitieren
APA
Dlouha, D., Pompach, P., Horackova, J., Hubacek, J. A., & Blaha, V. (2026). Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study. PROTEOMICS – Clinical Applications, 20(3). https://doi.org/10.1002/prca.70043
Vancouver
Dlouha D, Pompach P, Horackova J, Hubacek JA, Blaha V. Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study. PROTEOMICS – Clinical Applications. 2026;20(3). doi:10.1002/prca.70043
BibTeX
@article{Dlouha2026,
author = {Dlouha, Dana and Pompach, Petr and Horackova, Jana and Hubacek, Jaroslav Alois and Blaha, Vladimir},
title = {Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study},
journal = {PROTEOMICS – Clinical Applications},
year = {2026},
volume = {20},
number = {3},
doi = {10.1002/prca.70043}
}
EUVIMED